Acarix AB Q2 2026: Revenue Surges 102% as US Business Grows 223%, UAE Expansion Begins

Swedish cardiac diagnostics company Acarix AB posted a breakthrough Q2 2026 quarter, with revenue surging 102% year-over-year as its US business expanded 223% and the company entered the UAE market.

• Acarix (ACIXF) Q2 2026 revenue +102% YoY driven by 223% US growth and new UAE market entry
• Company advancing toward CPT1 reimbursement transition — key to US commercial scale-up
• Small-cap medical device maker showing momentum in cardiac acoustic diagnostics market

Acarix AB's Q2 2026 earnings call delivered numbers that significantly outpaced expectations for a micro-cap medical device company. The headline 102% revenue increase was driven primarily by its US commercial operations, which grew 223% year-over-year as the company's CADScor System — a non-invasive acoustic cardiac diagnostic device — gained traction among cardiology practices and health systems. The US growth came alongside simultaneous UAE market entry, demonstrating geographic diversification momentum.

The most strategically important development cited on the call was progress toward the CPT1 reimbursement milestone. In the US healthcare market, CPT coding and reimbursement status directly determines commercial viability at scale — without it, sales depend on out-of-pocket or research-use frameworks that cap addressable market. The company signaled it is on a trajectory to secure CPT1 classification, which would unlock hospital budgets and insurance reimbursement, dramatically expanding the pool of potential customers.

Investors in ACIXF should contextualize the high growth rates against a small absolute revenue base — 100%+ growth is easier to sustain early in a commercial ramp than at maturity. The UAE entry opens a Gulf healthcare market that has been aggressively investing in advanced diagnostics capacity, but the company will need to manage working capital carefully across multiple geographies simultaneously. The CPT1 approval timeline remains the pivotal catalyst, with any delay likely to weigh on US sales trajectory assumptions.

Synthesized from 1 source(s).